Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289780 · ClinicalTrials.gov registry record
Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects
A clinical trial of Non-Small Cell Lung Cancer, sponsored by Biodesix.
- Active
- Registry status
- 5,006
- Enrollment target
- 20
- Study locations
NCT03289780 is a study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Biodesix. The registered enrollment target is 5,006 participants, above the 648-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (673% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03289780, a study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Biodesix.
- ACTIVE NOT RECRUITING
- Registry status
- 5,006 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.
Conditions Studied
Study Locations (20)
Georgia
- South Eastern Regional Medical Center - Newnan
- Summit Cancer Care - Savannah
- South Georgia Medical Center - Valdosta
Alabama
- Oncology Specialties, PC; Clearview Cancer Institute - Huntsville
- Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center - Tuscaloosa
Arkansas
- Highlands Oncology Group - Fayetteville
- St. Bernards Cancer Center Hematology / Oncology - Jonesboro
Florida
- Boca Raton Regional Hospital -Lynn Cancer Institute - Boca Raton
- Lake City Cancer Care, LLC - Lake City
Illinois
- Edward-Elmhurst Healthcare - Naperville
- Illinois Cancer Care - Peoria
Indiana
- Franciscan St. Francis Health - Indianapolis
- Franciscan Health Woodland Cancer Center - Michigan City
Louisiana
- Ponchartrain Cancer Center - Covington
- Christus Health - Shreveport
Missouri
- Central Care Cancer Center - Bolivar
- Phelps County Regional Medical Center - Rolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,006 participants |
| Start Date | 2016-04-04 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03289780
The ClinicalTrials.gov registry entry for NCT03289780 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 5,006 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 648-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (673% higher). The listed sponsor is Biodesix, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03289780 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Georgia, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03289780 about?
NCT03289780 is a clinical study titled "Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects". The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to be...
What is the current status of trial NCT03289780?
This trial is currently active not recruiting. The enrollment target is 5,006 participants. The study started on 2016-04-04. Estimated completion is 2025-12.
What conditions does trial NCT03289780 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
Who is sponsoring clinical trial NCT03289780?
This trial is sponsored by Biodesix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03289780 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.